Column List | SMC Laboratories Inc.

2025.02.03

Nerandomilast: Breakthrough Success in Phase 3

We would like to introduce the data we obtained from a recently conducted bleomycin-induced lung fibrosis study using Nerandomilast. Nerandomilast is a compound expected to be approved soon as a treatment for IPF, following the previously approved Pirfenidone and Nintedanib. The mentioned therapeutic study using Nerandomilast in a bleomycin-induced lung fibrosis model that…

2025.02.02

Comparative Study of GLP-1 Agonists

Direct comparison study with GLP-1 agonist Today, we would like to introduce a demonstration example of a drug efficacy evaluation test targeting GLP-1 using STAMTM mouse. Liraglutide, the first GLP-1 agonist in Japan, was launched on the market in 2010, and since then Exenatide, Lixisenatide, etc. have appeared. As of January 2024, Table…

2025.02.02

Comparative Study of FGF21 agonist

Direct comparison study with FGF21 agonist Today, we would like to introduce a demonstration example of a drug efficacy evaluation study targeting FGF21 using STAMTM mice. In 2023, positive results were announced for Efruxifermin from Akero in the US and Pegozafermin from 89bio in Israel in Phase 2b, and future developments are expected. As…

2025.02.02

Sample delivery service of disease model mice

Today, we would like to proposal on how to utilize samples of our disease model mice. We have provided many drug efficacy evaluation studies, including our STAMTM model is the world’s first NASH to HCC mouse model developed by SMC Laboratories, which develops liver cancer from NASH (non-alcoholic steatohepatitis). We have received many requests…

2025.02.02

Comparison data between NASH-HCC patients and our NASH-HCC model

We have acquired the gene expression data (RNA-seq data) using our STAMTM model. Additionally, we have compared the gene expression data between the STAMTM model and NASH-HCC patients. As a result, we found that many of the gene expression changes were common in both the STAMTM model mice and NASH-HCC patients as well as…

2025.02.02

Drug Efficacy Studies in NASH Mouse Model

Today, we would like to introduce a study published by our client, Tsumura, in which they used our pre-clinical services (Ishizawa et al., Gene. 2022) to test their compound in our proprietary NASH model called STAMTM. To give you a little background on this model, the STAMTM mice have a diabetic background and follow…

2025.02.02

In-vivo screening and pharmacology study for liver cancer

We would like to introduce an in-vivo screening study using our liver orthotopic xenograft and STAM™ models. In case you are unfamiliar with these models, we would like to quickly present them, which could be extremely useful to you. ■ STAM™ The STAM™ was developed by SMC Laboratories as the world’s first mouse model…

2025.02.02

Pre-clinical studies for Liver Cancer: STAM model

For Today’s topic, I would like to focus on Hepatocellular Carcinoma (HCC). We have summarized the characteristics of the various liver cancer models, and you can learn more about them by clicking on the link below. If you are interested in learning about how to prevent and treat liver cancer, please read on. …

2025.02.02

Characterization of a lung fibrosis model and its usefulness

We offer the Idiopathic Pulmonary Fibrosis (IPF) model as a potential model for the development of therapeutics for lung fibrosis, and many of our customers have used this model through our introduction of its usefulness. What is Bleomycin-Induced model for Idiopathic Pulmonary Fibrosis? Bleomycin is a chemotherapeutic agent used to treat cancer, but…

2025.02.02

Interesting relevance between liver cancer patients and our cancer mouse model

Do you have any interest in liver cancer, hepatocellular carcinoma (HCC), or doing research about HCC? We hope the relevant information between HCC and the STAMTM model will be useful to you. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, the fifth most frequent form of cancer, and the third…